Ministers and Senior MPs Caution British Agreements with Donald Trump are 'Unstable'.

Ministers and senior MPs have issued warnings that the United Kingdom's recent agreements with the US administration are "fundamentally unstable." This stems from revelations that a much-touted deal on medicines, which pledges zero tariffs in exchange for the NHS facing higher prices, lacks any formal legal text beyond limited headline terms contained within government press releases.

Lacking Legal Footing

The US-UK pharmaceuticals agreement, hailed as a "generational" achievement, exists as an "agreement in principle" without a signed legal text. Critics have noted that the press releases from the UK and US governments describe the deal in sharply different terms. The British version celebrates securing "duty-free access" as a unique achievement, while the American announcement highlights the expectation for the NHS to pay significantly more for new medications.

"There is a serious risk that the UK government has made commitments to raise drug prices in return for only a pledge from President Trump," commented David Henig, a trade expert. "It is documented he has a tendency for not honouring his word."

Broader Instability and a Paused Tech Deal

Worries have been heightened by Washington's action to suspend the high-value digital accord, which was previously called "a transformative pact" in the bilateral relationship. The US pointed to a insufficient movement from the UK on reducing other tariffs as the reason for the pause.

Furthermore, concessions agreed to for British farmers as part of an earlier tariff deal have not been formally approved by the US, despite a looming January deadline. "Our understanding is that the US has not yet signed off the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Uncertainty Among Officials

Behind the scenes, ministers have expressed concerns that the government's US-UK accords are lacking substance. One minister was quoted as stating the series of agreements as "built on sand," while another described the situation as the "new normal" in the transatlantic relationship, marked by "greater risk and fluctuation."

Layla Moran, a senior MP on the health committee, argued: "The only thing more surprising than Trump's temper tantrums is the UK government's naive belief that his administration is a trustworthy negotiator. The NHS is too precious to be gambled with."

Government Downplays Risks, Points to Gains

Officials have sought to reduce the possibility of the US backing out of the pharmaceuticals deal. One source suggested the US pharmaceutical industry itself had been advocating for the agreement, desiring stability on imports and pricing, making it more concrete than the paused tech deal.

Officials concede that unpredictability is a feature of dealing with the current US leadership. However, they maintain that the UK has obtained tangible results for businesses, such as lower steel tariffs compared to other nations. "Our achievement of 25% steel tariffs, which is better than the rate for the rest of the world, is not flimsy," one official said.

Yet, delays have surfaced in enacting the initial US-UK accord. Promised quotas on beef exports have not materialized, and the pledge to "remove tariffs on British steel and aluminium" has not been fulfilled, with tariffs staying at 25%.

As negotiations continue, the two sides have planned to recommence talks on the paused tech prosperity deal in January, following what were described as "constructive" meetings between UK and US officials in Washington.